Nov 21, 2022 7:00 am EST Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
Nov 17, 2022 7:00 am EST Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
Nov 15, 2022 7:00 am EST Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
Nov 14, 2022 7:00 am EST Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
Oct 31, 2022 7:00 am EDT Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
Oct 27, 2022 7:00 am EDT Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Oct 25, 2022 7:00 am EDT New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
Oct 24, 2022 7:00 am EDT Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
